MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...

MSD has moved a step closer to completing its acquisition of Verona Pharma, after a vote in favour of the transaction by the UK company's shareholders. Investors in Verona – a specialist in ...